Why the study?
Does the concomitant use of clopidogrel and Proton Pump Inhibitors increase adverse cardiovascular outcomes in patients following percutaneous coronary intervention?
Does the concomitant use of clopidogrel and Proton Pump Inhibitors increase adverse cardiovascular outcomes in patients following percutaneous coronary intervention?
Concomitant use of clopidogrel and PPIs following PCI remains associated with an increased risk of MACE, stent thrombosis, and MI, supporting previous meta-analyses.
Supports caution with concomitant clopidogrel-PPI use post-PCI; reinforces prior meta-analyses on elevated MACE, ST, and MI risk.
The combined use of clopidogrel with PPIs is still associated with significantly higher adverse cardiovascular events such as MACEs, ST and MI following PCI supporting results of the previously published meta-analysis. However, long-term mortality is not statistically significant warranting further analysis with randomized patients.
No takes yet. Share an insight, caveat, or question.
Bundhun et al. (2017) studied this question.